Latest & greatest articles for prostate cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prostate cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on prostate cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for prostate cancer

141. Non-FDG tracers for use in PET-CT for suspected recurrent prostate cancer

Non-FDG tracers for use in PET-CT for suspected recurrent prostate cancer 67 1 technology description What is an evidence note? Evidence notes are rapid reviews of published secondary clinical and cost-effectiveness evidence on health technologies under consideration by decision makers within NHSScotland. They are intended to provide information quickly to support time-sensitive decisions. Information is available to the topic referrer within a 6 month period and the process of peer review (...) ? Several non-FDG tracers are available for use with PET-CT in the context of restaging suspected recurrence in patients previously treated for prostate cancer, including 11 C-choline, 18 F- fluoroethylcholine, 18 F- fluoromethylcholine, anti- 18 F-FACBC, and 68 Ga-PSMA. ? There is evidence for high sensitivity and specificity of choline-based tracers in detecting prostate cancer recurrence. ? 18 F-choline appears to be more effective than 11 C-choline in restaging prostate cancer. ? Based on a small

Evidence Notes from Healthcare Improvement Scotland2017

142. High-Intensity focused ultrasound for salvage therapy of recurrent prostate cancer

High-Intensity focused ultrasound for salvage therapy of recurrent prostate cancer High-Intensity focused ultrasound for salvage therapy of recurrent prostate cancer High-Intensity focused ultrasound for salvage therapy of recurrent prostate cancer HAYES, Inc Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc. High-Intensity focused ultrasound (...) for salvage therapy of recurrent prostate cancer. Lansdale: HAYES, Inc. Directory Publication. 2017 Authors' conclusions High-intensity focused ultrasound (HIFU) is a minimally invasive (transrectal) treatment that generates heat through sound energy to destroy tumor tissue. Sound waves produced by an ultrasonic transducer mounted on an endorectal probe penetrate the rectal wall and ablate either the entire prostate gland or focal areas containing tumor while avoiding damage to normal tissue. Rationale

Health Technology Assessment (HTA) Database.2017

143. The Fitbit One Physical Activity Tracker in Men With Prostate Cancer: Validation Study

The Fitbit One Physical Activity Tracker in Men With Prostate Cancer: Validation Study 28420602 2018 11 13 2369-1999 3 1 2017 Apr 18 JMIR cancer JMIR Cancer The Fitbit One Physical Activity Tracker in Men With Prostate Cancer: Validation Study. e5 10.2196/cancer.6935 Physical activity after cancer diagnosis improves quality of life and may lengthen survival. However, objective data in cancer survivors are limited and no physical activity tracker has been validated for use in this population (...) . The aim of this study was to validate the Fitbit One's measures of physical activity over 7 days in free-living men with localized prostate cancer. We validated the Fitbit One against the gold-standard ActiGraph GT3X+ accelerometer in 22 prostate cancer survivors under free-living conditions for 7 days. We also compared these devices with the HJ-322U Tri-axis USB Omron pedometer and a physical activity diary. We used descriptive statistics (eg, mean, standard deviation, median, interquartile range

JMIR cancer2017 Full Text: Link to full Text with Trip Pro

144. Hypofractionation trials and radiobiology of prostate cancer

Hypofractionation trials and radiobiology of prostate cancer 28540332 2018 11 13 2331-4737 4 3-4 2017 Mar Oncoscience Oncoscience Hypofractionation trials and radiobiology of prostate cancer. 27-28 10.18632/oncoscience.347 Gulliford Sarah S The Institute of Cancer Research, London, UK. Hall Emma E The Institute of Cancer Research, London, UK. Dearnaley David D The Institute of Cancer Research, London, UK. eng 7253 Cancer Research UK United Kingdom Editorial 2017 04 14 United States Oncoscience (...) 101636666 2331-4737 hypofractionation prostate CONFLICTS OF INTEREST DD and EH are Chief Investigator and Clinical Trial Unit Lead for the CHHiP Trial funded by Cancer Reesearch UK and SG, DD and EH acknowledge NHS funding to the NIHR Biomedical Research Centre at the Royal Marsden NHS Foundation Trust and Institute of Cancer Research. 2016 12 19 2017 03 25 2017 5 26 6 0 2017 5 26 6 0 2017 5 26 6 1 epublish 28540332 10.18632/oncoscience.347 347 PMC5441472 Lancet Oncol. 2016 Aug;17(8):1061-9 27339116

Oncoscience2017 Full Text: Link to full Text with Trip Pro

145. Shared Decision-Making in Patients With Prostate Cancer in Japan: Patient Preferences Versus Physician Perceptions

Shared Decision-Making in Patients With Prostate Cancer in Japan: Patient Preferences Versus Physician Perceptions 30241183 2018 12 07 2378-9506 4 2018 Sep Journal of global oncology J Glob Oncol Shared Decision-Making in Patients With Prostate Cancer in Japan: Patient Preferences Versus Physician Perceptions. 1-9 10.1200/JGO.2016.008045 This article adds the Japanese perspective to our knowledge of shared decision-making (SDM) preferences by surveying patients with prostate cancer (PCA (...) involvement in treatment decisions (a higher rate than in a similar study for the United States in 2001), almost half the Japanese patients preferred SDM, but only 33% of physicians assumed this was their choice. That is, 29% of Japanese physicians underestimated patients' preference for involvement in making treatment decisions. Patients with lower health-related quality of life (as measured by the Functional Assessment of Cancer Therapy-Prostate [FACT-P]) expressed a stronger preference for SDM

Journal of global oncology2017 Full Text: Link to full Text with Trip Pro

146. Brachytherapy for Patients with Prostate Cancer: American Society of Clinical Oncology/Cancer Care Ontario Joint Guideline Update

Brachytherapy for Patients with Prostate Cancer: American Society of Clinical Oncology/Cancer Care Ontario Joint Guideline Update Genitourinary Cancer | ASCO Search form Search ASCO Family of Sites ASCOconnection.org features blogs from ASCO members, the online version of the membership magazine, a discussion area, working groups, and links to the ASCO Membership Directory, Career Center, and Volunteer Portal. ASCO’s growing roster of cutting-edge journals serves readers as the most credible (...) , authoritative, peer-reviewed resources for significant clinical oncology research and research that informs the delivery of efficient, high-quality cancer care across the globe. ASCO University serves as a comprehensive eLearning and mobile learning center that supports lifelong learning for physicians, advanced practice providers, and patient educators at every stage of their careers. A cutting-edge health information technology platform, CancerLinQ™ enables practitioners to learn from individual patients

Cancer Care Ontario2017

147. Robot-Assisted Laparoscopic Prostatectomy in a Prostate Cancer Patient Undergoing Continuous Ambulatory Peritoneal Dialysis

Robot-Assisted Laparoscopic Prostatectomy in a Prostate Cancer Patient Undergoing Continuous Ambulatory Peritoneal Dialysis 28451644 2018 11 13 2379-9889 3 1 2017 Journal of endourology case reports J Endourol Case Rep Robot-Assisted Laparoscopic Prostatectomy in a Prostate Cancer Patient Undergoing Continuous Ambulatory Peritoneal Dialysis. 42-44 10.1089/cren.2017.0014 Background: Robot-assisted laparoscopic prostatectomy (RALP) has become the gold standard treatment for organ-confined (...) prostate cancer. However, no proper surgical approach or appropriate postsurgical management of RALP has been established for a patient undergoing peritoneal dialysis. Here, we present a case of a peritoneal dialysis patient who underwent RALP and reinstated peritoneal dialysis with no trouble associated with peritoneal dialysis. Case Presentation: The patient was a 61-year-old man with organ-confined prostate cancer. He had been on peritoneal dialysis for 2 years. The peritoneal dialysis catheter

Journal of endourology case reports2017 Full Text: Link to full Text with Trip Pro

148. Efficacy and Safety of Docetaxel in Elderly Patients With Metastatic Castration-Resistant Prostate Cancer

Efficacy and Safety of Docetaxel in Elderly Patients With Metastatic Castration-Resistant Prostate Cancer 30241182 2018 12 07 2378-9506 4 2018 Sep Journal of global oncology J Glob Oncol Efficacy and Safety of Docetaxel in Elderly Patients With Metastatic Castration-Resistant Prostate Cancer. 1-9 10.1200/JGO.2016.007807 Limited data are available about the tolerability and clinical outcomes of elderly patients with metastatic castration-resistant prostate cancer (mCRPC) who are treated (...) 0 ppublish 30241182 10.1200/JGO.2016.007807 PMC6180794 Int J Cancer. 2015 Mar 1;136(5):E359-86 25220842 Future Oncol. 2016 Feb;12(4):493-502 26776493 Clin Prostate Cancer. 2003 Dec;2(3):167-72 15040860 J Clin Oncol. 2011 Sep 1;29(25):3457-65 21810685 N Engl J Med. 2004 Oct 7;351(15):1502-12 15470213 Lancet Oncol. 2016 Feb;17(2):243-256 26718929 J Clin Oncol. 2008 Jan 10;26(2):242-5 18182665 N Engl J Med. 2004 Oct 7;351(15):1513-20 15470214 Urol Int. 2011;87(3):263-9 21876321 BJU Int. 2007 Feb;99

Journal of global oncology2017 Full Text: Link to full Text with Trip Pro

149. Association Between Choice of Radical Prostatectomy, External Beam Radiotherapy, Brachytherapy, or Active Surveillance and Patient-Reported Quality of Life Among Men With Localized Prostate Cancer.

Association Between Choice of Radical Prostatectomy, External Beam Radiotherapy, Brachytherapy, or Active Surveillance and Patient-Reported Quality of Life Among Men With Localized Prostate Cancer. Importance: Patients diagnosed with localized prostate cancer have to decide among treatment strategies that may differ in their likelihood of adverse effects. Objective: To compare quality of life (QOL) after radical prostatectomy, external beam radiotherapy, and brachytherapy vs active surveillance (...) . Design, Setting, and Participants: Population-based prospective cohort of 1141 men (57% participation among eligible men) with newly diagnosed prostate cancer were enrolled from January 2011 through June 2013 in collaboration with the North Carolina Central Cancer Registry. Median time from diagnosis to enrollment was 5 weeks, and all men were enrolled with written informed consent prior to treatment. Final follow-up date for current analysis was September 9, 2015. Exposures: Treatment with radical

JAMA2017

150. Association Between Radiation Therapy, Surgery, or Observation for Localized Prostate Cancer and Patient-Reported Outcomes After 3 Years.

Association Between Radiation Therapy, Surgery, or Observation for Localized Prostate Cancer and Patient-Reported Outcomes After 3 Years. Importance: Understanding the adverse effects of contemporary approaches to localized prostate cancer treatment could inform shared decision making. Objective: To compare functional outcomes and adverse effects associated with radical prostatectomy, external beam radiation therapy (EBRT), and active surveillance. Design, Setting, and Participants: Prospective (...) , population-based, cohort study involving 2550 men (≤80 years) diagnosed in 2011-2012 with clinical stage cT1-2, localized prostate cancer, with prostate-specific antigen levels less than 50 ng/mL, and enrolled within 6 months of diagnosis. Exposures: Treatment with radical prostatectomy, EBRT, or active surveillance was ascertained within 1 year of diagnosis. Main Outcomes and Measures: Patient-reported function on the 26-item Expanded Prostate Cancer Index Composite (EPIC) 36 months after enrollment

JAMA2017 Full Text: Link to full Text with Trip Pro

151. Prostate Cancer in Southern Africa: Does Africa Hold Untapped Potential to Add Value to the Current Understanding of a Common Disease?

Prostate Cancer in Southern Africa: Does Africa Hold Untapped Potential to Add Value to the Current Understanding of a Common Disease? 30241160 2018 12 07 2378-9506 4 2018 Sep Journal of global oncology J Glob Oncol Prostate Cancer in Southern Africa: Does Africa Hold Untapped Potential to Add Value to the Current Understanding of a Common Disease? 1-7 10.1200/JGO.2016.008862 Hayes Vanessa M VM Vanessa M. Hayes, University of Sydney, University of New South Wales, and Garvan Institute (...) 17176219 BJU Int. 2010 Aug;106(3):405-11 19849691 Lancet Glob Health. 2016 Sep;4(9):e609-16 27470177 BJU Int. 2005 Jul;96(1):29-33 15963115 Rural Remote Health. 2014;14:2378 24815856 BMC Urol. 2013 Dec 29;13:74 24373635 Nat Genet. 2013 Apr;45(4):385-91, 391e1-2 23535732 Am J Epidemiol. 2011 Jun 1;173(11):1280-8 21447478 PLoS One. 2011 Jan 06;6(1):e14495 21253579 Prostate Cancer. 2011;2011:947870 22111004 Nat Genet. 2016 Jan;48(1):30-5 26569126 Hum Genet. 2014 May;133(5):509-21 24185611 Transcult

Journal of global oncology2017 Full Text: Link to full Text with Trip Pro

152. ACR Appropriateness Criteria for external beam radiation therapy treatment planning for clinically localized prostate cancer, part II of II

ACR Appropriateness Criteria for external beam radiation therapy treatment planning for clinically localized prostate cancer, part II of II 29114613 2018 11 13 2452-1094 2 3 2017 Jul-Sep Advances in radiation oncology Adv Radiat Oncol ACR Appropriateness Criteria for external beam radiation therapy treatment planning for clinically localized prostate cancer, part II of II. 437-454 10.1016/j.adro.2017.03.003 To present the most updated American College of Radiology (ACR) Appropriateness Criteria (...) formed by an expert panel on the appropriate delivery of external beam radiation to manage stage T1 and T2 prostate cancer (in the definitive setting and post-prostatectomy) and to provide clinical variants with expert recommendations based on accompanying Appropriateness Criteria for target volumes and treatment planning. The ACR Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a panel of multidisciplinary experts. The guideline

Advances in radiation oncology2017 Full Text: Link to full Text with Trip Pro

153. Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy

Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy 28303694 2017 04 25 2018 11 13 2051-3909 64 1 2017 Mar Journal of medical radiation sciences J Med Radiat Sci Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy. 52-60 10.1002/jmrs.227 Prostate-specific membrane antigen (PSMA) is a receptor (...) on the surface of prostate cancer cells that is revolutionising the way we image and treat men with prostate cancer. New small molecule peptides with high-binding affinity for the PSMA receptor have allowed high quality, highly specific PET imaging, in addition to the development of targeted radionuclide therapy for men with prostate cancer. This targeted therapy for prostate cancer has, to date, predominately used Lutetium 177 (Lu) labelled PSMA peptides. Early clinical studies evaluating the safety

Journal of medical radiation sciences2017 Full Text: Link to full Text with Trip Pro

154. First Australian experience of treating localised prostate cancer patients with CyberKnife stereotactic radiotherapy: early PSA response, acute toxicity and quality of life

First Australian experience of treating localised prostate cancer patients with CyberKnife stereotactic radiotherapy: early PSA response, acute toxicity and quality of life 28271639 2018 04 30 2018 11 13 2051-3909 64 3 2017 Sep Journal of medical radiation sciences J Med Radiat Sci First Australian experience of treating localised prostate cancer patients with CyberKnife stereotactic radiotherapy: early PSA response, acute toxicity and quality of life. 180-187 10.1002/jmrs.205 This study (...) is to evaluate biochemical response, acute toxicity and health-related quality-of-life (QOL) outcomes among prostate cancer patients following stereotactic body radiation therapy (SBRT) in the first Australian CyberKnife facility. Forty-five consecutive patients with clinically localised prostate cancer were treated with SBRT using CyberKnife technology and enrolled in this study. Protocol treatment consisted of 36.25 Gy in five fractions. PSA and acute toxicity was assessed at each follow-up visit and QOL

Journal of medical radiation sciences2017 Full Text: Link to full Text with Trip Pro

155. Initial experience with intra‐fraction motion monitoring using Calypso guided volumetric modulated arc therapy for definitive prostate cancer treatment

Initial experience with intra‐fraction motion monitoring using Calypso guided volumetric modulated arc therapy for definitive prostate cancer treatment 28263041 2017 04 25 2018 12 02 2051-3909 64 1 2017 Mar Journal of medical radiation sciences J Med Radiat Sci Initial experience with intra-fraction motion monitoring using Calypso guided volumetric modulated arc therapy for definitive prostate cancer treatment. 25-34 10.1002/jmrs.224 Accurate delivery of radiation while reducing dose (...) Leonards, New South Wales, Australia. Barnes Mardi M Northern Sydney Cancer Centre, Radiation Oncology Department, Royal North Shore Hospital, St Leonards, New South Wales, Australia. Booth Jeremy T JT Northern Sydney Cancer Centre, Radiation Oncology Department, Royal North Shore Hospital, St Leonards, New South Wales, Australia. eng Journal Article 2017 03 06 United States J Med Radiat Sci 101620352 2051-3895 IM Dose Fractionation, Radiation Humans Male Movement Prostatic Neoplasms physiopathology

Journal of medical radiation sciences2017 Full Text: Link to full Text with Trip Pro

156. Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer

Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer 28034081 2016 12 30 2017 02 10 1527-7755 35 1 2017 Jan Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic (...) Chemotherapy-Naive Castration-Resistant Prostate Cancer. 40-47 Purpose Ipilimumab increases antitumor T-cell responses by binding to cytotoxic T-lymphocyte antigen 4. We evaluated treatment with ipilimumab in asymptomatic or minimally symptomatic patients with chemotherapy-naive metastatic castration-resistant prostate cancer without visceral metastases. Patients and Methods In this multicenter, double-blind, phase III trial, patients were randomly assigned (2:1) to ipilimumab 10 mg/kg or placebo every 3

EvidenceUpdates2017

157. Triptorelin (Decapeptyl SR) - prostate cancer

Triptorelin (Decapeptyl SR) - prostate cancer Final Appraisal Recommendation Advice No: 0417 – February 2017 Triptorelin (Decapeptyl ® SR) 3 mg and 11.25 mg powder for suspension for injections, 22.5 mg powder and solvent for suspension for injection Limited submission by Ipsen Ltd Additional note(s): • Please refer to the Summary of Product Characteristics for the full licensed indication. In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared (...) advanced prostate cancer and as neoadjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced prostate cancer.

All Wales Medicines Strategy Group2017

158. Diffusion-weighted endorectal MR imaging at 3T for prostate cancer: Correlation with tumor cell density and percentage Gleason pattern on whole mount pathology

Diffusion-weighted endorectal MR imaging at 3T for prostate cancer: Correlation with tumor cell density and percentage Gleason pattern on whole mount pathology 27770164 2018 03 28 2018 11 13 2366-0058 42 3 2017 03 Abdominal radiology (New York) Abdom Radiol (NY) Diffusion-weighted endorectal MR imaging at 3T for prostate cancer: correlation with tumor cell density and percentage Gleason pattern on whole mount pathology. 918-925 10.1007/s00261-016-0942-1 To determine if tumor cell density (...) and percentage of Gleason pattern within an outlined volumetric tumor region of interest (TROI) on whole-mount pathology (WMP) correlate with apparent diffusion coefficient (ADC) values on corresponding TROIs outlined on pre-operative MRI. Men with biopsy-proven prostate adenocarcinoma undergoing multiparametric MRI (mpMRI) prior to prostatectomy were consented to this prospective study. WMP and mpMRI images were viewed using 3D Slicer and each TROI from WMP was contoured on the high b-value ADC maps (b0

Abdominal radiology (New York)2017 Full Text: Link to full Text with Trip Pro

159. Pretreatment prostate specific antigen doubling time as prognostic factor in prostate cancer patients

Pretreatment prostate specific antigen doubling time as prognostic factor in prostate cancer patients 28484728 2018 11 13 2331-4737 4 1-2 2017 Jan Oncoscience Oncoscience Pretreatment prostate specific antigen doubling time as prognostic factor in prostate cancer patients. 7-13 10.18632/oncoscience.337 Despite the prostate-specific antigen (PSA) serum level commonly uses as tumor marker in diagnosis of prostate cancer, it seems that PSA doubling time (PSADT) could be more useful indicator (...) of tumor behavior and of prognosis for patients. The results of hormone and radiation therapy were evaluated for 912 prostate cancer having at least 2 PSA tests before the treatment was started. Clustering procedure (selection of homogenous group) was performed by using PSADT as the classification marker. The rate of PSADT was estimated for different dissemination rate, age, Gleasons's score and education level. PSADT index inversely correlated with the rate of prostate cancer dissemination, Gleason's

Oncoscience2017 Full Text: Link to full Text with Trip Pro

160. Switching from an LHRH Antagonist to an LHRH Agonist: A Case Report of 10 Finnish Patients with Advanced Prostate Cancer

Switching from an LHRH Antagonist to an LHRH Agonist: A Case Report of 10 Finnish Patients with Advanced Prostate Cancer 28680962 2018 11 13 2366-1070 5 1 2017 Oncology and therapy Oncol Ther Switching from an LHRH Antagonist to an LHRH Agonist: A Case Report of 10 Finnish Patients with Advanced Prostate Cancer. 119-123 10.1007/s40487-017-0040-8 Luteinizing hormone-releasing hormone (LHRH) analogues are widely used for the treatment of advanced hormone-dependent prostate cancer. However (...) , there are currently no clinical guidelines for switching between LHRH analogues. It has been reported that there may be clinical benefits for patients switching between different formulations of LHRH agonists, as well as from an LHRH agonist to LHRH antagonist, but there are no published data on switching from an LHRH antagonist to an LHRH agonist. In this paper, we summarize the clinical notes of 10 patients with hormone-sensitive advanced prostate cancer who switched from an LHRH antagonist to an LHRH agonist

Oncology and therapy2017 Full Text: Link to full Text with Trip Pro